Abstract
- Background
Dyslipidemia is widely recognized as one of the most critical and frequent modifiable risk factors contributing to the pathogenesis and progression of atherosclerosis and cardiovascular disease. Emblica officinalis (Amla, or Indian gooseberry) possesses a rich medicinal heritage in traditional systems and is heavily enriched with bioactive polyphenols, triterpenoids, and essential phytonutrients. This clinical trial was designed to evaluate the therapeutic efficacy and metabolic impact of a standardized Amla fruit extract on serum lipid profiles, apolipoprotein ratios, oxidative markers, and glycemic control in patients diagnosed with dyslipidemia.
- Methods
A total of ninety-eight dyslipidemic adult patients were enrolled in this study and randomly allocated into the Amla treatment group or a matching placebo group. Participants in the active intervention arm received 500 mg of standardized Amla extract administered orally twice daily over a 12-week consecutive intervention period. Comprehensive clinical follow-ups and biochemical evaluations were conducted to assess therapeutic efficacy by analyzing standard lipid profile parameters—including total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and very low-density lipoprotein cholesterol (VLDL-C). Secondary exploratory and safety endpoints included apolipoprotein B (Apo B), apolipoprotein A1 (Apo A1), atherogenic index of plasma (AIP), coenzyme Q10 (CoQ10) levels, high-sensitivity C-reactive protein (hs-CRP), fasting blood sugar (FBS), plasma homocysteine, and thyroid-stimulating hormone (TSH).
- Results
Following the 12-week intervention, patients in the Amla extract group demonstrated statistically significant improvements in all major lipid parameters compared to the placebo cohort. Specifically, marked reductions were observed in serum total cholesterol ($P = 0.0003$), triglycerides ($P = 0.0003$), LDL-C ($P = 0.0064$), and VLDL-C ($P = 0.0001$). Furthermore, the Amla group exhibited a striking 39% reduction in the atherogenic index of plasma (AIP) ($P = 0.0177$) alongside a favorable, near-significant decrease in the Apo B-to-Apo A1 ratio ($P = 0.0866$). Notably, circulating Coenzyme Q10 levels remained entirely unaffected by Amla supplementation ($P = 0.2942$), contrasting sharply with the depletions typically observed under conventional statin therapy. While baseline-adjusted fasting blood sugar exhibited a general downward trend, subgroup evaluations among participants with elevated baseline FBS ($>100\text{ mg/dL}$) highlighted its potential ancillary hypoglycemic utility, warranting larger confirmatory studies.
- Conclusions
Standardized Emblica officinalis (Amla) extract demonstrates robust clinical potential in significantly reducing total cholesterol, triglycerides, atherogenic lipid ratios, and apoB/apoA-I levels in dyslipidemic individuals. Its dual capacity to lower both cholesterol and triglycerides—without concomitantly depleting vital Coenzyme Q10 reserves—establishes Amla extract as a rare, highly promising therapeutic botanical agent for managing both general and diabetic dyslipidemia.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6341673/